Intellia Therapeutics, Inc.
NTLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $57,877 | $36,275 | $52,121 | $33,053 |
| % Growth | 59.6% | -30.4% | 57.7% | – |
| Cost of Goods Sold | $10,285 | $8,976 | $7,572 | $6,891 |
| Gross Profit | $47,592 | $27,299 | $44,549 | $26,162 |
| % Margin | 82.2% | 75.3% | 85.5% | 79.2% |
| R&D Expenses | $466,311 | $435,069 | $419,979 | $229,807 |
| G&A Expenses | $125,829 | $116,497 | $90,306 | $71,096 |
| SG&A Expenses | $125,829 | $116,497 | $90,306 | $71,096 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$10,285 | -$8,976 | -$7,572 | -$6,891 |
| Operating Expenses | $581,855 | $542,590 | $502,713 | $294,012 |
| Operating Income | -$534,263 | -$515,291 | -$458,164 | -$267,850 |
| % Margin | -923.1% | -1,420.5% | -879% | -810.4% |
| Other Income/Exp. Net | $15,242 | $34,099 | -$16,022 | -$42 |
| Pre-Tax Income | -$519,021 | -$481,192 | -$474,186 | -$267,892 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$519,021 | -$481,192 | -$474,186 | -$267,892 |
| % Margin | -896.8% | -1,326.5% | -909.8% | -810.5% |
| EPS | -5.25 | -5.42 | -6.16 | -3.78 |
| % Growth | 3.1% | 12% | -63% | – |
| EPS Diluted | -5.25 | -5.42 | -6.16 | -3.78 |
| Weighted Avg Shares Out | 98,849 | 88,770 | 76,972 | 70,894 |
| Weighted Avg Shares Out Dil | 98,849 | 88,770 | 76,972 | 70,894 |
| Supplemental Information | – | – | – | – |
| Interest Income | $47,807 | $49,832 | $8,542 | $1,283 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $10,285 | $8,976 | $7,572 | $6,891 |
| EBITDA | -$523,978 | -$506,315 | -$450,592 | -$260,959 |
| % Margin | -905.3% | -1,395.8% | -864.5% | -789.5% |